Amgen Inc. (NASDAQ: AMGN), whose bone pain drug, Xgeva, failed to get an FDA panel’s approval for use as a treatment for prostate cancer, is most often mentioned as a potential suitor for Dendreon. Dendreon’s market cap of around $1.5 billion is well within Amgen’s scope.
Dendreon’s shares are up more than 4.5% at $10.39 in a 52-week range of $6.46-$43.96.
Paul Ausick has been writing for a673b.bigscoots-temp.com for more than a decade. He has written extensively on investing in the energy, defense, and technology sectors. In a previous life, he wrote technical documentation and managed a marketing communications group in Silicon Valley.
He has a bachelor's degree in English from the University of Chicago and now lives in Montana, where he fishes for trout in the summer and stays inside during the winter.
Our top personal finance-related articles today. Your wallet will thank you later.
Top Gaining Stocks
Top Losing Stocks